DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

What is the ALEMBIC PHARMA LTD (APLLTD) share price today?

ALEMBIC PHARMA LTD (APLLTD) is trading at ₹825.1 on the NSE, down 1.74% on the day. Source: DocStoX.

What is the PE ratio of ALEMBIC PHARMA LTD?

ALEMBIC PHARMA LTD has a price-to-earnings (PE) ratio of 24.0 in the Healthcare sector.

What is the market capitalisation of ALEMBIC PHARMA LTD?

ALEMBIC PHARMA LTD has a market capitalisation of approximately ₹16,212 crore.

ALEMBIC PHARMA LTD

APLLTD·NSE·Healthcare

₹825.10▼ -14.65 (-1.74%)

Healthcare · Pharmaceuticals

A steady, established business

Day₹821.00

₹842.85

52W₹636

₹104446%

Open

₹842.85

High

₹842.85

Low

₹821.00

Prev Close

₹839.75

Volume

70.7K

VWAP

₹826.04

Snapshot

Key fundamentals

Market Cap

₹16,212 Cr

P/E Ratio

24.03Fair

P/B Ratio

2.83

EPS

₹34.33

Book Value

₹289.00

ROE

13.40%Average

ROCE

13.00%Decent

Dividend Yield

1.35%

Debt / Equity

0.25Low

Face Value

₹2.00

52W High

₹1044.00

52W Low

₹635.80

Sector

Healthcare

Industry

Pharmaceuticals

Avoid

None moatHigh uncertainty

Fair value estimate

₹334

▼ 59.5%downside

Trading at ₹825 — 59% above our estimate

BearFair valueBull

₹284₹334₹472

/100

Business quality — Solid

Growth 68Profitability 41Efficiency 13Valuation 76

Plain English

Our view

A steady, established business
Low debt relative to equity
Fundamental red flags (Piotroski 2/9)

Strengths

Low debt relative to equity
Profit growing 25% a year
Promoters hold a controlling stake

Risks

Fundamental red flags (Piotroski 2/9)

How we got there

Fair value methods

Residual income

13% ROE fading to 12% over ~3 yrs, on ₹289 book

₹296

Relative P/E

Needs ≥3 peers with P/E

—

Graham floor

Conservative floor: √(22.5 × EPS × book value/share)

₹472

Analyst target

No analyst coverage

—

Blended fair value₹334

What the numbers say

Investment thesis

Bull case

Low debt relative to equity
Profit growing 25% a year
Promoters hold a controlling stake

Bear case

Fundamental red flags (Piotroski 2/9)

Free — see our deterministic Fair Value range, business quality score, and the full bull/bear case for this stock.

Snapshot

Key statistics

P/E

24.0Fair

Below 15× is value territory; above 35× prices in strong growth

ROE

13.4%Average

Above 15% is considered healthy for Indian equities

ROCE

13.0%Decent

Above 18% means capital is working hard

Debt/Eq

0.25Low

Below 0.5 is comfortable; above 1.5 strains the balance sheet

Mkt Cap

₹16,212 Cr

P/B

2.83

EPS

₹34.33

Div Yield

1.35%

What changed

Recent changes

Domestic institutions-0.2% stake last quarter
Promoters+0.13% stake last quarter

What matters

News impact

Overview

Valuation

Reasonable

P/E 24.0×

Growth

Steady

+9% rev CAGR

Profitability

Healthy

13.4% ROE

Financial health

Rock solid

D/E 0.25

Momentum

N/A

No technicals

Today

Trading activity

Delivery %50.1%

Turnover₹584.37L Cr

Trades6,175

VWAP₹826.04

Face value₹2.00

Market depth

Market depth available during market hours

Snapshot

Technical signals

Compounded annual growth

Growth (CAGR)

Revenue

+9.1%

+6.4%

10Y

+8.8%

Profit

+25.2%

-10.2%

10Y

-0.7%

EPS

+25.4%

-10.1%

10Y

-1.1%

Profile

Pros

Company has been maintaining a healthy dividend payout of 35.7%

Watch-outs

Cons

Stock is trading at 2.90 times its book value
The company has delivered a poor sales growth of 6.37% over past five years.
Tax rate seems low
Company has a low return on equity of 12.7% over last 3 years.
Company might be capitalizing the interest cost

Forecast

News

Peers

Financials

Growth

Shareholding

Ownership

Ownership breakdown

Quarter ending 30 Jun 2026

Promoters raised their stake by 0.13 pts; domestic institutions reduced 0.24 pts last quarter. The QoQ column shows each group's change versus the prior quarter.

70%

Promoter

Promoters

69.9%+0.13

Public

10.0%+0.17

FII / FPI

4.2%-0.09

DII

15.9%-0.24

Quarterly trend

Ownership over time

Q1 FY27

Promoter69.87%

FII4.17%

DII15.93%

Public10.00%

Corporate Actions

Bulk & Block Deals

Filings

MF Holdings

Technicals

FAQs

Quick reference

Frequently asked questions